Клинические рекомендации по диагностике и лечению диабетической нефропатии

1. Shestakova M., Mukhin N.I. Dedov V. Titov et al. Protein-loading test, urinary albumin excretion and renal morphology in diagnosis of subclinical diabetic nephropathy. J. Int. Med., 1992; 231 (3): 213- 217

2. Горашко Н.М., Шестакова М.В., Чистяков Д.А. и соавт. Ассоциация полиморфных генов генов-кандидатов с диабетической нефропатией у больных сахарным диабетом 1 типа. Сахарный диабет 2002; (1): 38-44 [Gorashko N.M., Shestakova M.V., Chistiakov D.A. i soavt. Assotciatciia polimorfny'kh genov genov-kandidatov s diabeticheskoi' nefropatiei' u bol'ny'kh saharny'm diabetom 1 tipa. Saharny'i' diabet 2002; (1): 38-44]

3. Шестакова М.В., Кошель Л.В., Вагодин В.А., Дедов И.И. Факторы риска прогрессирования диабетической нефропатии у больных с длительным течением сахарного диабета по данным ретроспективного анализа. Тер. архив 2006; (5): 60-64 [Shestakova M.V., Koshel' L.V., Vagodin V.A., Dedov I.I. Faktory' riska progressirovaniia diabeticheskoi' nefropatii u bol'ny'kh s dlitel'ny'm techeniem saharnogo diabeta po danny'm retrospetivnogo analiza. Ter. Arhiv 2006; (5): 60-64].

4. Тpофименко И.И., Добpонpавов В.А., Быстрова Н.Н. и др. Pаспpостpаненность снижения скоpости клубочковой фильтpации у больных сахаpным диабетом Тер. Архив. 2008; 6: 48-52 [Tpofimenko I.I., Dobponpavov V.A., By'stpova N.N. et al. Pasppostpanennost' snizheniia skoposti clubochkovoi' fil'tpatcii u bol'ny'kh sahapny'm diabetom Ter. Arhiv. 2008;6: 48-52]

5. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J. 2007; 28(1):88-136.

6. K/DOQI dinical Practice Guidelines and dinical Practice Recommendations for Diabetes and Chronic Kidney Disease Am J Kidney Dis 2007; 49: S1-S179.

7. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60 (5):850-886.

8. American Diabetes Association. Diabetes 2001 Vital Statistics. Alexandria, VA, ADA, 2001 9. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 2004; 27: (Suppl. 1): S15-S35,

9. American Diabetes Association: Hypertension management in adults with diabetes (Position Statement). Diabetes Care 2004; 27 (Suppl. 1):S65-S67,

10. Bakris GL, Williams M, Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis 2000; 36:646-661,

11. Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type

12. diabetes and nephropathy. N Engl J Med 2001; 345:861-869,

13. DeFronzo RA: Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995; 3:510-564

14. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329:977-986,

15. Lewis EJ, Hunsicker LG, Clarke WR. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345:851-860,

16. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462,

17. Mogensen CE, Keane WF, Bennett PH. et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346:1080-1084,

18. Mogensen CE, Neldam S, Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000; 1440-1444,

19. Parving HH, Lehnert H, Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878,

20. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317:713-720,

21. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853,

22. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998 317:703-713,

23. Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia. 1992; Sep;35(9):803-812

24. Osterby R, Nyberg G, Karlberg I, Svalander C. Glomerular volume in kidneys transplanted into diabetic and non-diabetic patients. Diabet Med. 1992; Mar;9(2):144-149.

25. Mauer SM, Bilous RW, Ellis E. et al. Some lessons from the studies of renal biopsies in patients with insulin-dependent diabetes mellitus. J Diabet Complications. 1988;2(4):197-202.

26. Matsumae T, Jimi S, Uesugi N. et al. Clinical and morphometrical interrelationships in patients with overt nephropathy induced by non-insulin-dependent diabetes mellitus. A light- and electron-microscopy study. Nephron. 1999;81(1):41-48.

27. Solini A, Dalla Vestra M, Saller A. et al. The angiotensinconverting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes. 2002;51(1):251-255.

28. Wirta OR, Pasternack AI, Mustonen JT. et al. Urinary albumin excretion rate and its determinants after 6 years in noninsulin-dependent diabetic patients. Nephrol Dial Transplant. 1996;11(3):449-456.

29. Wirta O, Pasternack A, Laippala P, Turjanmaa V. Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol. 1996;45(1):10-17.

30. Deferrari G, Repetto M, Calvi C. et al. Diabetic nephropathy: from micro- to macroalbuminuria. Nephrol Dial Transplant. 1998;13 Suppl 8:11-15.

31. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7(1):35-43.

32. Klausen KP, Parving HH, Scharling H, Jensen JS. The association betweenmetabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med. 2007;262(4):470-478.

33. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition ofmicroalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension. 2005 Jul;46(1):33-37.

34. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32-35.

35. Gall MA. Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan Med Bull. 1997 Nov;44(5):465-485. Review. PubMed PMID: 9408734.

36. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783-788.

37. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996;156(3):286-289.

38. Eknoyan G, Hostetter T, Bakris GL. et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42(4):617-622.

39. Mogensen CE, Keane WF, Bennett PH. et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346(8982):1080-1084.

40. Pedrini MT, Levey AS, Lau J. et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124(7):627-632.

41. Gross JL, Zelmanovitz T, Moulin CC. et al. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. Diabetes Care. 2002;25(4):645-651.

42. Diabetes Control and Complications Trial/Epidemiology of Diabetes interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).Arch Intern Med. 2009;169(14):1307-1316.

43. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.

44. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167

45. Delahanty LM, Halford BN. The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care. 1993;16(11):1453-1458.

46. Anderson EJ, Richardson M, Castle G. et al. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc. 1993;93(7):768-772.

47. Watkins P. The UKPDS. A model for gathering the evidence for the management of chronic diseases. UK Prospective Diabetes Study Group. J R Coll Physicians Lond. 1998;32(6):510-511.

48. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998;352(9139):1558.

49. Intensive blood-glucose control with sulphonyl urea’s or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999;354(9178):602.

50. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):720-726

51. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-720.

52. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12;317(7160):703-13. Erratum in: BMJ 1999;318(7175):29.

53. Manley S. Haemoglobin A1c - a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med.2003; 41(9):1182-1190.

54. Vandenhaute V. Palliative care and type II diabetes: A need for new guidelines? Am J Hosp Palliat Care. 2010;27(7):444-445.

55. Schwartz V. [Critical notes on the results of studies (ACCORD, ADVANCE, VADT)of the efficiency of intensive therapy of type 2 diabetes mellitus]. Klin Med(Mosk). 2011;89(3):18-20. Review. Russian.

56. Chalmers J, Joshi R, Kengne AP, MacMahon S. Blood pressure lowering withfixed combination perindopril-indapamide: key findings from ADVANCE. J Hypertens Suppl. 2008;26(2):S11-15.

57. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S,Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcmes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.

58. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect ofangiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-1462. Erratum in:N Engl J Med 1993;330(2):152.

59. Laffel LM, McGill JB, Gans DJ. The beneficial effect ofangiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995 ;99(5):497-504.

60. Brenner BM, Cooper ME, de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.

61. Mogensen CE. Diabetic nephropathy: evidence for renoprotection and practice. Heart. 2000 ;84 Suppl 1:i26-28

62. Mogensen CE. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. J Renin Angiotensin Aldosterone Syst. 2000;1(3):234-239.

63. Mogensen CE, Neldam S, Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.

64. Fried LF, Forrest KY, Ellis D. et al. Lipidmodulation in insulindependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications. 2001;15(3):113-119.

65. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on theprogression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260-269.

66. Collins R, Armitage J, Parish S. et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.

67. Predictors of the development of microalbuminuria in patients with Type I diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet Med. 1999;16(11):918-925.

68. Gall MA, Hougaard P, Borch-Johnsen K. et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783-788.

69. Gerstein HC, Mann JF, Yi Q, Zinman B. et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-426.

70. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-349.

71. Bakris GL et al. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998;11(10):158S-162S.